Your browser is no longer supported. Please, upgrade your browser.
NEW! Auto Refresh is now available in Screener. Let us know what you think. ×
ABBV AbbVie Inc. daily Stock Chart
AbbVie Inc.
IndexS&P 500 P/E35.26 EPS (ttm)1.71 Insider Own0.10% Shs Outstand1.63B Perf Week-1.15%
Market Cap98.56B Forward P/E12.47 EPS next Y4.83 Insider Trans-3.82% Shs Float1.61B Perf Month14.66%
Income2.82B PEG2.03 EPS next Q1.12 Inst Own72.10% Short Float1.23% Perf Quarter-5.68%
Sales21.91B P/S4.50 EPS this Y-57.20% Inst Trans-5.11% Short Ratio1.83 Perf Half Y-7.95%
Book/sh2.94 P/B20.51 EPS next Y12.95% ROA6.90% Target Price75.29 Perf Year-8.51%
Cash/sh5.66 P/C10.66 EPS next 5Y17.39% ROE83.60% 52W Range45.45 - 70.95 Perf YTD-4.84%
Dividend2.28 P/FCF- EPS past 5Y-17.80% ROI16.80% 52W High-15.02% Beta-
Dividend %3.78% Quick Ratio1.80 Sales past 5Y7.00% Gross Margin81.50% 52W Low32.65% ATR1.96
Employees26000 Current Ratio2.00 Sales Q/Q18.40% Oper. Margin22.90% RSI (14)55.18 Volatility1.69% 2.83%
OptionableYes Debt/Eq6.61 EPS Q/Q138.70% Profit Margin12.90% Rel Volume0.45 Prev Close61.13
ShortableYes LT Debt/Eq6.45 EarningsOct 30 BMO Payout113.40% Avg Volume10.89M Price60.29
Recom2.10 SMA20-0.78% SMA505.16% SMA200-2.47% Volume4,867,978 Change-1.37%
Nov-02-15Upgrade Morgan Stanley Equal-Weight → Overweight
Oct-23-15Reiterated UBS Buy $81 → $78
Sep-28-15Upgrade Citigroup Sell → Neutral
Jul-22-15Initiated Sun Trust Rbsn Humphrey Buy
Jun-17-15Initiated Piper Jaffray Overweight
Jun-08-15Reiterated Jefferies Buy $86 → $90
May-28-15Resumed Morgan Stanley Equal-Weight $72
May-27-15Resumed JP Morgan Overweight $75
Jan-06-15Reiterated UBS Buy $72 → $76
Nov-26-14Reiterated Argus Buy $65 → $85
Nov-14-14Initiated Deutsche Bank Buy $80
Jul-28-14Upgrade UBS Neutral → Buy $57 → $67
Jun-24-14Reiterated Argus Buy $59 → $65
Jan-06-14Reiterated UBS Neutral $46 → $56
Oct-29-13Reiterated Argus Buy $52 → $59
Aug-12-13Initiated Argus Buy $52
May-15-13Reiterated R. F. Lafferty Buy $47.90 → $61
Apr-29-13Reiterated Barclays Equal Weight $41 → $44
Apr-15-13Reiterated Barclays Equal Weight $37 → $41
Nov-26-15 10:06AM  Novartis: Market Responds to European Commissions Cosentyx Approval
09:03AM  Gilead Sciences Grabs 4 Regulatory Wins -- but Does It Matter? at Motley Fool
12:04AM  Keytruda: Hope for Mercks Immuno-Oncology Franchise
12:04AM  Remicade: A Falling Drug in Mercks Immunology Franchise
Nov-25-15 04:27PM  Amgen applies to FDA for competitor drug to AbbVie's Humira at MarketWatch
04:11PM  Amgen files for U.S. approval of biosimilar to Humira Reuters
09:43AM  Big Pharma has become addicted to an illusion at Financial Times
09:17AM  Billionaire Larry Robbins Has Mixed Sentiment On His Top Picks For Q4 at Insider Monkey
08:30AM  How I Plan To Uncover 2016's Best Stocks
Nov-24-15 09:30AM  Zacks Industry Outlook Highlights: Valeant, Pfizer, Allergan, AbbVie and Gilead
Nov-23-15 10:01AM  Can Merck & Co. Take Down Gilead Sciences? at Motley Fool
Nov-21-15 09:04AM  Gilead Sciences Inc. Has Plenty of Room to Run in Hepatitis C at Motley Fool
Nov-20-15 06:19PM  Glenview's Larry Robbins Lowers Drug Manufacturers, Raises Providers
02:14PM  Gilead Sciences: Hepatitis-C Prescriptions Increase at
08:34AM  Health care is the best pick for 2016, despite Thursday's drop: Strategist
Nov-19-15 07:05PM  Pfizer-Allergan A Go Despite New Tax Inversion Rules? at Investor's Business Daily
02:30PM  Gilead Leads a Biotech Rally at TheStreet
11:28AM  Pfizer, Allergan Near Deal Despite Treasury Warning at Investor's Business Daily
09:30AM  The Zacks Analyst Blog Highlights: Clovis Oncology, Gilead, AbbVie and Medicines Company
Nov-18-15 06:05PM  Treasury Plans New 'Targeted' Tax-Inversion Crackdown at Investor's Business Daily
03:09PM  Biotech Stock Roundup: Clovis Plunges, Label Expansion for Gilead's Harvoni
12:20PM  Infinity (INFI) Completes Enrollment in Phase III DUO Study
12:10PM  Gilead Seen Staying Top Dog In HCV, But Merck Rising at Investor's Business Daily
09:10AM  Jefferies Reveals Top 5 Pharma Stock Picks for Growth and Dividends at 24/7 Wall St.
Nov-17-15 05:00PM  Gilead's Leukemia Study Unblinded Early on Positive Data
03:38PM  Top healthcare stock fund focuses on costs, orphan drugs in 2016 Reuters
01:18PM  AbbVie: An Attractive Setup? at
Nov-16-15 05:27PM  AbbVie Reports Encouraging Data on HCV Drug Viekira Pak
02:06PM  Celgenes Operating Expenses in 3Q15
09:19AM  3 High-Yield Dividend Stocks You Don't Have to Babysit at Motley Fool
09:00AM  AbbVie Announces High Sustained Virologic Response Rates in Phase 2 Studies with Pan-genotypic, Investigational Regimen in Patients with Chronic Hepatitis C PR Newswire
06:15AM  Lets Hope the Fed Doesn't Make a Second Mistake!
Nov-15-15 10:02AM  Billionaire Jim Simons Top High-Dividend Stock Picks at Insider Monkey
Nov-14-15 08:12PM  1 Stock to Settle the Dividend vs. Buyback Debate at Forbes
09:01AM  AbbVie Announces New Data on VIEKIRA PAK® (ombitasvir, paritaprevir, ritonavir tablets; dasabuvir tablets) in Patients with Chronic Hepatitis C Virus Infection With or Without Compensated Cirrhosis PR Newswire
Nov-13-15 01:22PM  Gilead Sciences: Good Bye Genotype Testing? at
01:04PM  ABBVIE INC. Financials
11:06AM  Celgene Has a Strong Inflammation and Immunology Pipeline
08:41AM  Hepatitis C Treatment in 2016: Will Gilead Sciences or AbbVie Win? at Motley Fool
08:00AM  AbbVie Submits IMBRUVICA® (ibrutinib) Phase III Combination Data to U.S. FDA PR Newswire
04:06AM  Otezla Delivers Robust Revenue in 3Q15
Nov-12-15 10:37AM  Merck & Co. Versus AbbVie: Who Is the Winner and Who Is the Loser?
10:01AM  Gilead Sciences: What's Next for Hepatitis C? at
Nov-11-15 08:15AM  Short Sellers Continue to Decrease Bets in Major Pharma at 24/7 Wall St.
08:01AM  Should Healthcare Dividend Hunters Target AbbVie or Johnson & Johnson? at Motley Fool
Nov-10-15 10:35AM  Top Technology Stock Removed From Jefferies Franchise Picks List at 24/7 Wall St.
08:55AM  Top Analyst Upgrades and Downgrades: AbbVie, Apple, Autodesk,, CyberArk, Dean Foods, Disney and More at 24/7 Wall St.
Nov-09-15 12:35PM  AbbVie: Five Reasons for Comfort at
10:09AM  How Might the First Trust Value Line Dividend Index Fund Benefit Investors?
07:56AM  5 Big Rocket Stocks to Buy in November at TheStreet
04:30AM  What Does One Quarter or Half Percent Really Mean? Nothing!
Nov-07-15 02:25PM  Here Are This Elite Funds Top Stock Picks at Insider Monkey
12:07AM  AbbVie Topped XBIs Large-Cap Space
Nov-06-15 04:47PM  A Fund Flow Analysis of the First Trust Value Line Dividend Index Fund
01:43PM  ABBVIE INC. Files SEC form 10-Q, Quarterly Report
10:43AM  Are Beech Hill Advisors Top Biotech Stock Picks Poised For A Big Q4? at Insider Monkey
Nov-05-15 04:54PM  Gilead, AbbVie Asked by U.S. for Hepatitis C Pricing Options at Bloomberg
04:30PM  Gilead's Sovaldi in Focus on Bradyarrhythmia Concerns
10:30AM  AbbVie's Commitment to Oncology Demonstrated at the 57th American Society of Hematology Annual Meeting with 61 Abstracts Evaluating Medicines in Several Blood Cancers PR Newswire
10:09AM  Amgen Continues to Control Operating Expenses in 3Q15
09:30AM  The Zacks Analyst Blog Highlights: AbbVie, Amgen, Dyax, Repros and Gilead
09:06AM  Does AbbVie's Viekira Pak Warning Land Express Scripts in the Penalty Box? at Motley Fool
08:08AM  What Were Pfizers Key Growth Contributors in 3Q15?
08:00AM  AbbVie to Present at Jefferies Autumn 2015 Global Healthcare Conference in London PR Newswire
Nov-04-15 07:05PM  Cramer Remix: This group's about to be hammered at CNBC
06:53PM  Lightning Round: The best stock nobody talks about at CNBC
05:00PM  Gilead's Sovaldi Tied to Slow Heartbeat in Hepatitis C Patients at Bloomberg
10:41AM  Biotech Stock Roundup: AbbVie's Humira Remains Strong, Shire to Buy Dyax
10:20AM  Chinas November 2015 PMI Pressured Oil Prices, US Market Bullish
10:08AM  Gilead Sciences Continued Liver Disease Research in 3Q15
Nov-03-15 10:19AM  Valeants use of specialty pharmacy channel is typical of the industry at MarketWatch
10:10AM  Enbrel Boosts Amgens Revenues in the Anti-Inflammation Segment
09:23AM  Woodford Investment Management Has A Lot Riding On These 5 Stocks at Insider Monkey
08:00AM  AbbVie's Leadership and Innovation in Immunology Showcased at the American College of Rheumatology Annual Meeting with More Than 40 Abstracts on HUMIRA® (adalimumab) and Investigational Medicines Across Multiple Inflammatory Diseases PR Newswire
Nov-02-15 05:00PM  AbbVie, Lead Performer of the Pharmaceutical Subgroup +6.43%
02:23PM  Street Talk: Retrophin under the radar
12:38PM  AbbVie: Increased Clarity Brings Increased Comfort at
12:04PM  AbbVie to Present at Credit Suisse 24th Annual Healthcare Conference PR Newswire
11:16AM  Here's Why AbbVie (ABBV) Stock is Advancing Today at TheStreet
10:11AM  AbbVie: Is The 3Q Stock Rally Sustainable?
10:10AM  Company News for November 02, 2015
07:59AM  Which Dividends Would Be Safest If Drug Prices Were Slashed Tomorrow? at Motley Fool
06:46AM  [$$] Gilead Sciences Could Be Big in Japan at
06:01AM  Monetary Policies, Financial Markets and More
12:59AM  [$$] Overheard: AbbVies Shares Rise on Guidance at The Wall Street Journal
12:58AM  Drug Makers Buy Pricey Vouchers to Speed Products to Market at The Wall Street Journal
Nov-01-15 11:47PM  [$$] Business Watch: News Digest at The Wall Street Journal
11:00PM  South Africa Asked to Allow Generics for AbbVie HIV Drug at Bloomberg
10:21PM  [$$] Business Watch at The Wall Street Journal
08:31PM  Drug Makers Buy Pricey Vouchers to Speed Products to Market at The Wall Street Journal
02:02PM  AbbVie Calms Humira Biosimilar Fears at The Wall Street Journal
01:40PM  3 Drugs That Are About to Become Billion-Dollar Blockbusters in 2016 at Motley Fool
Oct-31-15 07:20AM  Gilead Sciences Is Shrugging Off Its Competitors at Motley Fool
Oct-30-15 04:41PM  US STOCKS-Stocks slip but post best month in four years Reuters +10.07%
04:18PM  [$$] Abbvie Rally Shows No Signs of Slowing Down at
03:58PM  [$$] AbbVie Profit Tops Estimates at The Wall Street Journal
03:34PM  US stocks slip as they finish a historically strong October
03:00PM  US STOCKS-Stocks inch lower, still track to best month in 4 years Reuters
02:12PM  Why AbbVie Inc. Shares Are Surging 10% Higher Today at Motley Fool
02:08PM  AbbVie beats Street 3Q forecasts, gets a lift from Humira
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company's products include HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; VIEKIRA PAK, an all-oral, short-course, interferon-free therapy, with or without ribavirin, for adult patients with genotype 1 chronic hepatitis, including those with compensated cirrhosis; Kaletra, an anti-HIV-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in people with HIV-1; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1 infection; and Synagis to prevent respiratory syncytial virus infection in high risk infants. It also provides AndroGel, a testosterone replacement therapy for males diagnosed with symptomatic low testosterone; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron, a product for the palliative treatment of prostate cancer, and the treatment of endometriosis and central precocious puberty, as well as for the preoperative treatment of patients with anemia. In addition, the company offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product for human use; TriCor, Trilipix, Niaspan, Simcor, and Advicor to treat metabolic conditions characterized by high cholesterol and/or high triglycerides; and Zemplar to treat secondary hyperparathyroidism. It sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. The company has strategic collaboration with Calico Life Sciences LLC, Infinity Pharmaceuticals, Inc., Ablynx NV, Galapagos NV, Alvine Pharmaceuticals, Inc., and Action Pharma A/S. AbbVie Inc. was incorporated in 2012 and is based in North Chicago, Illinois.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GONZALEZ RICHARD AChairman of the Board and CEOJul 29Option Exercise35.8865,0002,332,200538,187Jul 31 05:41 PM
GONZALEZ RICHARD AChairman of the Board and CEOJul 29Sale71.0924,9791,775,656513,208Jul 31 05:41 PM
GONZALEZ RICHARD AChairman of the Board and CEOJul 29Sale71.2440,0212,851,264473,187Jul 31 05:41 PM
HURWICH THOMAS A.VP, ControllerMay 19Option Exercise22.946,200142,23274,660May 21 05:50 PM
HURWICH THOMAS A.VP, ControllerMay 19Sale66.006,200409,20068,460May 21 05:50 PM
GONZALEZ RICHARD AChairman of the Board and CEOApr 28Option Exercise35.88175,4776,296,115657,624Apr 30 06:01 PM
GONZALEZ RICHARD AChairman of the Board and CEOApr 28Sale64.6795,9706,206,473554,660Apr 30 06:01 PM
GONZALEZ RICHARD AChairman of the Board and CEOApr 28Sale64.928,281537,569482,147Apr 30 06:02 PM
GONZALEZ RICHARD AChairman of the Board and CEOApr 08Sale64.726,994452,652561,360Apr 30 06:01 PM
Schumacher Laura JEVP, Bus.Dev.,Ext.Aff.&GCMar 02Sale60.3025,0001,507,500274,116Mar 03 06:10 PM
RICHMOND TIMOTHY J.SVP, Human ResourcesMar 02Sale60.3012,314742,534106,954Mar 03 06:07 PM
SALEKI-GERHARDT AZITASVP, OperationsFeb 27Sale60.472,112127,706104,555Mar 03 06:09 PM
RICHMOND TIMOTHY J.SVP, Human ResourcesFeb 27Sale60.512,074125,492123,860Mar 03 06:07 PM
HURWICH THOMAS A.VP, ControllerFeb 27Sale60.571,18571,77770,322Mar 03 06:06 PM
RICHMOND TIMOTHY J.SVP, Human ResourcesFeb 17Sale58.7024114,147106,592Feb 19 05:51 PM
SALEKI-GERHARDT AZITASVP, OperationsFeb 09Option Exercise24.072,25054,1643,168Feb 11 05:28 PM
CHASE WILLIAM JEVP, Chief Financial OfficerDec 22Option Exercise24.078,495204,501188,563Dec 22 05:22 PM
CHASE WILLIAM JEVP, Chief Financial OfficerDec 22Sale68.008,495577,660180,068Dec 22 05:22 PM